-transparent.png){kind=logo}
OBJECTIVE To study the effects and serum levels of glibenclamide (Gb) and its active metabolites in patients on chronic Gb medication on different daily doses. METHODS Fifty patients with type 2 diabetes on regular Gb therapy (1.75-14.0 mg daily). Blood samples were taken immediately before and 90 min after regular Gb intake. A standardized breakfast was served 30 min after drug intake. Serum insulin and proinsulin levels were determined by ELISA methods without cross-reactivities. Serum drug levels were determined by HPLC. Fischer's R to Z-test (correlation coefficients) and paired Student t-tests were used when comparing values within the entire group and unpaired non-parametric Mann-Whitney tests were used when comparing high and low dose levels. A p-value < 0.05 was considered significant. RESULTS There were significant correlations between daily Gb dose, on the one hand, and, on the other, HbAlc (r = 0.55), Delta-insulin (r = - 0.59) and Delta-proinsulin (r = - 0.52) levels. Significant correlations between Gb therapy duration and insulin (r = - 0.40) and proinsulin (r = - 0.34) secretion and between Gb dose and ratio proinsulin/insulin (RPI) at both time points (r = 0.32 and 0.30) were also found. The RPI was lower after Gb intake. In patients on > or = 10.5 mg steady state serum metabolite levels (Ml and Ml + M2) were higher (29(0-120) and 33 (0-120) ng/ml) than those of Gb itself (18(0-64) ng/ml). A great inter-subject variability in Gb levels at both time points was seen. CONCLUSIONS Our results indicate that, in patients on chronic medication, Gb is capable of stimulating both insulin and proinsulin secretion; the effect on insulin release is relatively greater. The effect was more pronounced in patients on a low Gb dose, either because of less impaired beta-cells in those receiving low doses, or due to reduced sulphonylurea sensitivity in those on high dosage (down-regulation). In patients on a daily dose of 10.5 mg or more, serum metabolite levels of clinical relevance were demonstrated; the metabolites may contribute to hypoglycaemic events.
A Jönsson, and
B Hallengren, and
T Rydberg, and
A Melander
April 2022,
The Journal of the Association of Physicians of India,
A Jönsson, and
B Hallengren, and
T Rydberg, and
A Melander
January 2017,
Clinical proteomics,
A Jönsson, and
B Hallengren, and
T Rydberg, and
A Melander
May 2012,
Saudi medical journal,
A Jönsson, and
B Hallengren, and
T Rydberg, and
A Melander
January 2010,
Angiology,
A Jönsson, and
B Hallengren, and
T Rydberg, and
A Melander
November 2016,
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists,
A Jönsson, and
B Hallengren, and
T Rydberg, and
A Melander
March 2002,
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
A Jönsson, and
B Hallengren, and
T Rydberg, and
A Melander
January 1977,
Arzneimittel-Forschung,
A Jönsson, and
B Hallengren, and
T Rydberg, and
A Melander
March 1998,
Diabetic medicine : a journal of the British Diabetic Association,
A Jönsson, and
B Hallengren, and
T Rydberg, and
A Melander
April 2013,
Atherosclerosis,
A Jönsson, and
B Hallengren, and
T Rydberg, and
A Melander
September 2008,
Metabolism: clinical and experimental,
